Text Size
1241 studies found for:    EGFR

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Not yet recruiting C11-Erlotinib PET/CT as a Tool for Identification and Characterization of Tumor With High Expression of Epidermal Growth Factor Receptor(EGFR).
Conditions: Lung Cancer;   Pancreatic Cancer
Intervention: Other: C11-Erlotinib PET/CT
22 Completed Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention:
23 Completed
Has Results 		Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors
Condition: Skin Toxicities
Intervention: Other: Questionnaire
24 Completed Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients
Condition: Solid Tumor
Interventions: Drug: enzyme inhibitor therapy;   Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy
25 Recruiting Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas
Condition: Non-small Cell Lung Cancer Metastatic
Intervention: Biological: CTC
26 Not yet recruiting Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma
Conditions: Squamous Cell Carcinoma;   Head and Neck Cancer
Intervention: Biological: EGFR Antisense DNA
27 Recruiting Detecting EGFR T790M Mutations From Circulating Tumor Cells
Condition: Non Small Cell Lung Cancer
Intervention: Device: Circulating tumor cell chip
28 Completed Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m
Condition: Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer
Intervention:
29 Recruiting Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR
Condition: Stage IV Lung Cancer
Interventions: Drug: Gefitinib;   Drug: Fulvestrant;   Drug: Erlotinib
30 Recruiting Retrospective Study in a NSCLC M+ p
Condition: EGFR Mutated Non-small Cell Lung Cancer Patients
Intervention:
31 Recruiting Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer;   EGFR Tyrosine Kinase Inhibitor 324674
Intervention: Drug: BIBW 2992
32 Not yet recruiting Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study
Condition: EGFR Mutation Positive Non Small Cell Lung Cancer
Intervention:
33 Active, not recruiting Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Erlotinib
34 Recruiting Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy
Condition: Non Small Cell Lung Cancer
Interventions: Drug: combined group;   Drug: Sequenced group
35 Terminated
Has Results 		Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Tarceva
36 Completed Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer
Condition: Stage IV Non-small Cell Lung Cancer
Intervention: Drug: Cetuximab in combination with Carboplatin/Gemcitabine
37 Completed Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
Conditions: Renal Insufficiency, Chronic;   Diabetes Mellitus, Type 2
Intervention: Drug: Bardoxolone methyl (amorphous dispersion)
38 Active, not recruiting Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Condition: Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Intervention: Drug: Gefitinib
39 Unknown † Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib
Condition: Non-Small Cell Lung Cancer
Intervention:
40 Unknown † A Retrospective Molecular Epidemiology Study in Singapore Patients With Advanced Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status
Condition: NSCLC
Intervention: Other: EGFR mutation status in patients
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years